MAO‐B inhibitors (e.g., selegiline, rasagiline, safinamide) prevent dopamine breakdown, thereby prolonging dopaminergic activity and reducing oxidative stress, which is implicated in PD progression [7]. The gene discussed is MAOB; the disease is Parkinson disease.